MC1742

Research use only, not for human use.

MC1742 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.1, 0.11, 0.02, and 0.61 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 7 and 40 nM for HDAC6 and HDAC10, respectively).

MC1742 is a potent HDAC inhibitor, with IC50s of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 and HDAC11, respectively. MC1742 can increase acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells growth. MC1742 can induce growth arrest, apoptosis, and differentiation in sarcoma CSC.

MC1742 (compound 1) (0.5 and 2 μM; 24 hours) increases acetylation in a dose-dependent manner, observable as punctuate nuclear staining of acetyl-histone H3.MC1742 (0.5, 1 and 2 μM; 24, 48 and 72 hours) significantly induces apoptosis of all CSC cultures.MC1742 (0.025-0.5 μM; 14 days) enhances bone nodule formation in a significantdose-dependent manner.Immunofluorescence Cell Line:Sarcoma cancer stem cells Concentration:0.5 and 2 μM Incubation Time:24 hours Result:Increased acetylation in a dose-dependent manner, observable as punctuate nuclear staining of acetyl-histone H3.Apoptosis Analysis Cell Line:Sarcoma cancer stem cells Concentration:0.5, 1 and 2 μM Incubation Time:24, 48 and 72 hours Result:Significantly induced apoptosis of all CSC cultures.Cell Differentiation Assay Cell Line:Sarcoma cancer stem cells Concentration:0.025, 0.05, 0.1 and 0.5 μM Incubation Time:14 days Result:Successfully enhanced bone nodule formation in a significantdose-dependent manner.

——

——

Others

Other Targets

Others

——

——

1776116-74-5

395.47

C21H21N3O3S

>98% (HPLC)

In Vitro:?DMSO : 200 mg/mL (505.73 mM; Ultrasonic )

S(CCCCC(NO)=O)C=1NC(=CC(=O)N1)C2=CC=C(C=C2)C3=CC=CC=C3

——

(-20℃)

With Ice Pack

≥ 2 years